Heart failure & cardiomyopathies
Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia
Authors' conclusion
In patients with HFrEF and HK or past HK receiving suboptimal RAS inhibitor/MRA therapy, RAS inhibitor/MRA optimization increased during patiromer-facilitated run-in.
Study context
- Population
- Patients with heart failure with reduced ejection fraction (HFrEF) and hyperkalemia (HK) or past HK receiving patiromer during the DIAMOND run-in (≤12 weeks)completed run-in
- Participants
- 1,038 patients
- Comparison
- Randomized vs run-in failure patients during patiromer-facilitated run-in
- Randomizedn = 878
- Run-in failuren = 160reference
- Primary endpoint
- Target RAS inhibitor and MRA use
- Follow-up
- Start to end of run-in
Methodological detailsrun-in phase analysis
- Run-in phase analysis
Primary result
As reported in the abstract
Target RAS inhibitor and MRA use, start to end of run-in
| Group | Renin-angiotensin system (RAS) inhibitor, HK | Mineralocorticoid receptor antagonist (MRA), HK | RAS inhibitor, past HK | MRA, past HK | RAS inhibitor | MRA |
|---|---|---|---|---|---|---|
| Randomized | 76.8% to 98.6% | 35.9% to 98.6% | 60.5% to 98.1% | 15.6% to 98.7% | ||
| Run-in failure | 51.5% to 64.7% | 19.1% to 39.7% | 53.3% to 75.0% | 12.0% to 54.3% | 52.5% to 70.6% | 15.0% to 48.1% |
Renin-angiotensin system (RAS) inhibitor, HK
Randomized76.8% to 98.6%
Run-in failure51.5% to 64.7%
Mineralocorticoid receptor antagonist (MRA), HK
Randomized35.9% to 98.6%
Run-in failure19.1% to 39.7%
RAS inhibitor, past HK
Randomized60.5% to 98.1%
Run-in failure53.3% to 75.0%
MRA, past HK
Randomized15.6% to 98.7%
Run-in failure12.0% to 54.3%
RAS inhibitor
Randomized— not stated in the abstract
Run-in failure52.5% to 70.6%
MRA
Randomized— not stated in the abstract
Run-in failure15.0% to 48.1%
Further findings
HK entering run-in · start of run-in
P = 0.605
- HK entering run-in — Overall HK entering run-in
- 422 (40.7%)
Original publication
Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia. J Am Coll Cardiol. Published 1 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →